Increased prevalence of autoimmune disease in patients with unilateral compared with bilateral moyamoya disease
- PMID: 26406790
- DOI: 10.3171/2015.4.JNS142936
Increased prevalence of autoimmune disease in patients with unilateral compared with bilateral moyamoya disease
Abstract
OBJECT This study explored whether there were differences between the autoimmune disease prevalence rates in unilateral and bilateral moyamoya disease (MMD). METHODS The authors performed a retrospective review of data obtained from the medical records of their hospital, analyzing and comparing the clinical characteristics and prevalence rates of all autoimmune diseases that were associated with unilateral and bilateral MMD in their hospital from January 1995 to October 2014. RESULTS Three hundred sixteen patients with bilateral MMD and 68 with unilateral MMD were identified. The results indicated that patients with unilateral MMD were more likely to be female than were patients with bilateral MMD (67.6% vs 51.3%, p = 0.014, odds ratio [OR] 1.99). Overall, non-autoimmune comorbidities tended to be more prevalent in the unilateral MMD cases than in the bilateral MMD cases (17.6% vs 9.8%, p = 0.063, OR 1.97, chi-square test). Autoimmune thyroid disease and other autoimmune diseases also tended to be more prevalent in the unilateral MMD cases than in the bilateral MMD cases (19.1% vs 10.8%, p = 0.056, OR 1.96 and 8.8% vs 3.5%, p = 0.092, OR 2.77, respectively, chi-square test). The overall autoimmune disease prevalence in the unilateral MMD cases was significantly higher than in the bilateral MMD cases (26.5% vs 13.6%, p = 0.008, OR 2.29, 95% CI 1.22-4.28, chi-square test). Multiple logistic regression analysis showed that autoimmune disease was more likely to be associated with unilateral than with bilateral MMD (p = 0.039, OR 10.91, 95% CI 1.13-105.25). CONCLUSIONS This study indicated a higher overall autoimmune disease prevalence in unilateral than in bilateral MMD. Unilateral MMD may be more associated with autoimmune disease than bilateral MMD. Different pathogenetic mechanisms may underlie moyamoya vessel formation in unilateral and bilateral MMD.
Keywords: AIG = autoimmune gastritis; APAS = antiphospholipid antibody syndrome; APS = autoimmune polyendocrine syndrome; GD = Graves’ disease; HT = Hashimoto thyroiditis; ICA = internal carotid artery; ICD-10 = International Classification of Diseases, 10th Revision; MCA= middle cerebral artery; MMD = moyamoya disease; MMV = moyamoya vasculopathy; PBC = primary biliary cirrhosis; SLE = systemic lupus erythematosus; TIA = transient ischemic attack; autoimmune; bilateral; moyamoya; pathogenesis; prevalence; unilateral; vascular disorders.
Similar articles
-
Prevalence of autoimmune disease in moyamoya disease patients in Western Chinese population.J Neurol Sci. 2015 Apr 15;351(1-2):184-186. doi: 10.1016/j.jns.2015.02.037. Epub 2015 Feb 26. J Neurol Sci. 2015. PMID: 25743224
-
Clinical features and disease progression in moyamoya disease patients with Graves disease.J Neurosurg. 2015 Oct;123(4):848-55. doi: 10.3171/2014.10.JNS141140. Epub 2015 Apr 10. J Neurosurg. 2015. PMID: 25859801
-
Clinical features and long-term outcomes of moyamoya disease: a single-center experience with 528 cases in China.J Neurosurg. 2015 Feb;122(2):392-9. doi: 10.3171/2014.10.JNS132369. Epub 2014 Nov 28. J Neurosurg. 2015. PMID: 25423267
-
An update on the diagnosis and treatment of adult Moyamoya disease taking into consideration controversial issues.Neurol Res. 2014 May;36(5):407-16. doi: 10.1179/1743132814Y.0000000351. Epub 2014 Mar 18. Neurol Res. 2014. PMID: 24641716 Review.
-
Moyamoya disease: a summary.Neurosurg Focus. 2009 Apr;26(4):E11. doi: 10.3171/2009.1.FOCUS08310. Neurosurg Focus. 2009. PMID: 19335127 Review.
Cited by
-
Synergistic Interaction of Thyroid Autoantibodies and Ring Finger Protein 213 Variant in Moyamoya Disease.Neurol Med Chir (Tokyo). 2024 Jan 15;64(1):43-49. doi: 10.2176/jns-nmc.2023-0169. Epub 2023 Dec 6. Neurol Med Chir (Tokyo). 2024. PMID: 38057092 Free PMC article.
-
Research progress on moyamoya disease combined with thyroid diseases.Front Endocrinol (Lausanne). 2023 Oct 11;14:1233567. doi: 10.3389/fendo.2023.1233567. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37900127 Free PMC article. Review.
-
Physiological and pathophysiological mechanisms of the molecular and cellular biology of angiogenesis and inflammation in moyamoya angiopathy and related vascular diseases.Front Neurol. 2023 May 16;14:661611. doi: 10.3389/fneur.2023.661611. eCollection 2023. Front Neurol. 2023. PMID: 37273690 Free PMC article. Review.
-
Unusual presentation of acquired thrombotic thrombocytopenic purpura (TTP) versus catastrophic antiphospholipid syndrome in a patient with Moya-Moya disease, case report, and literature review.Clin Case Rep. 2023 May 12;11(5):e7317. doi: 10.1002/ccr3.7317. eCollection 2023 May. Clin Case Rep. 2023. PMID: 37192853 Free PMC article.
-
Experimental Animal Models for Moyamoya Disease: A Species-Oriented Scoping Review.Front Surg. 2022 Jul 1;9:929871. doi: 10.3389/fsurg.2022.929871. eCollection 2022. Front Surg. 2022. PMID: 35846951 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
